$NVMI

Oppenhaim Eitan sold $750K of NVMI

Oppenhaim Eitan sold 1,290 shares of NOVA LTD. (NVMI) at $581.20 ($0.75M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Oppenhaim Eitan
Published Jun 24, 2026, 6:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVMI
Neutral
medium confidence
Mentioned
$NVMI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVMINeutralLow
01

Why it matters

The newest fact is the reported open-market sale (1,290 shares) and the post-sale holdings (6,421 shares), under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a major repricing.

03

What to watch

Without context on total insider holdings, prior sale cadence, or whether other insiders also sold/bought, the signal-to-noise for price impact remains low.

Relevance 4/10Novelty 4/10Timing: Filed 2026-06-24; transaction dated 2026-06-22.

Background

The article is an SEC Form 4 insider transaction disclosure for NOVA LTD. (NVMI) by director Oppenhaim Eitan.

Company-level read

Ticker impact

$NVMINeutralMedium confidence
Context

Form 4 shows director Oppenhaim Eitan sold 1,290 NVMI shares in an open-market sale for about $749,748 on 2026-06-22.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No sector-level read-across is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A large insider sale can still be interpreted as risk-reduction or liquidity needs, but the presence of a pre-arranged 10b5-1 plan weakens that inference.

Key entities

  • NVMI

    NOVA LTD., the issuer of the Form 4 insider transaction.

  • Oppenhaim Eitan

    Director who executed the reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVMIMedAI 8/10

Nova (NVMI) Just Blew Past $250M In Quarterly Sales

Nova (NVMI) reported Q2 2026 revenue of $255M, up 8% QoQ and 16% YoY, with GAAP net income of $75M and non-GAAP net income of $86.5M. GAAP EPS was $2.20, up from $2.04 QoQ and $2.14 YoY. Non-GAAP EPS was $2.51, up from $2.33 QoQ and $2.20 YoY. The company guided Q3 2026 revenue to $277M-$287M, GAAP EPS to $2.46-$2.61, and non-GAAP EPS to $2.70-$2.85. Gross margin declined to 56.5% from 57.7% QoQ and 57.8% YoY.

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$NVMIHigh

NOVA LTD. (NVMI): Financial results for Q2 2026

NOVA LTD. (NVMI) furnished an SEC Form 6-K — earnings release. Attached hereto and incorporated by way of reference herein is a press release issued by the Registrant and entitled: “Nova Reports Record Second Quarter 2026 Financial Results”. The GAAP financial statements tables included in the press release attached hereto are hereby incorpo

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.